Powered 500 · 2026POWEREDS. 325 of 500
By building antibody-discovery tools and taking equity stakes in the biotech companies that use them, Anderson has turned Alloy into a picks-and-shovels platform with exposure to hundreds of drug programs simultaneously — without the binary risk of developing a single asset.
Errik Anderson co-founded and leads Alloy Therapeutics, a Massachusetts biotech platform company building tools and services for antibody, gene therapy, and small molecule drug discovery.
Alloy licenses its antibody discovery platform and takes equity stakes in drug developers that use its tools, partnering with major pharmas and emerging biotechs. Anderson was named a 2025 EY Entrepreneur of the Year New England Award winner.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
